

Liver Cancer Mortality Rates in Peru: Trend Analysis from 2003 to 2017

J. Smith Torres-Roman^{1*}, Gabriel De la Cruz-Ku^{1,2}, Christian S. Alvarez³, Jorge Ybaseta-Medina⁴, Eloy F. Ruiz^{2,5}, José Fabian Martinez-Herrera^{2,6}, Janina Bazalar-Palacios^{2,7}, Lita Del Rio-Muñoz^{2,8}, Julio A. Poterico⁹, Katherine A. McGlynn³

Abstract

Background: Liver cancer is one of the leading causes of cancer-related death in Peru, and some reports have indicated an increase in mortality rates among the largest cities. To our knowledge, no study has been carried out at a national level or by geographic area in recent years. Thus, our objective was to examine overall, regional and sex-specific liver cancer mortality rates in Peru between 2003-2017. **Methods:** We retrieved data on liver cancer deaths between 2003 and 2017 from the mortality database of the Peruvian Ministry of Health. Age-standardized mortality rates (ASMR) were estimated per 100,000 person-years using the world standard SEGI population. We analyzed mortality trends using Joinpoint regression Program Version 4.7.0. To examine the spatial distribution of the mortality rates, we used GeoDa software. **Results:** Between 2003 and 2017, 31,473 deaths from liver cancer were reported in Peru. Overall, liver cancer mortality rates have decreased significantly among Peruvian women since 2005 (-3.1% annually) with decreases in the coastal and highland regions ranging from 2.8% to 3.5%. In Arequipa, Cusco, La Libertad, Lima, and Moquegua, rates decreased between 2003 and 2017. Among men in Ancash a significant increase (+12.5 annually) was observed from 2003-2011, followed by a sharp decline (-10.5 annually) between 2011 and 2017. In contrast, rates in Cajamarca, Junin, and Ucayali decreased between 2003 and 2017. **Conclusions:** Although decreases in liver cancer mortality rates were observed in some regions of Peru, these trends were not statistically significant. In addition, some provinces experienced increases in rates. Effective interventions, such as expanding access to healthcare and controlling the various risk factors for liver cancer, remains a key challenge for the country.

Keywords: Liver cancer- Geographic spatial analysis- Mortality rate- Epidemiology- Peru

Asian Pac J Cancer Prev, 26 (2), 435-441

Introduction

Worldwide, liver cancer is the eighth most commonly occurring malignant neoplasm, and the fourth leading cause of cancer-related death with more than 866,000 new cases (age-standardized incidence rate of 8.6 per 100,000) and more than 758,000 deaths (age-standardized mortality rate of 7.4 per 100,000) in 2022 [1].

The major risk factors associated with liver cancer are hepatitis B (HBV) and hepatitis C (HCV) virus infections [2, 3], metabolic dysfunction-associated steatotic liver disease (MASLD) [4-6], excess body weight [7, 8], type

2 diabetes mellitus [9], excessive alcohol consumption [10], smoking [11, 12], and aflatoxin B1 (AFB1) exposure [13, 14]. However, these factors vary in their distribution around the world [15].

In recent years, the burden of liver cancer has increased in countries with perceived low risk, likely explained by changes in diet, weight gain, and the increase in prevalence of non-communicable conditions such as diabetes and MASLD. Latin American countries stand out as they still maintain a high mortality rate compared to other regions [16, 17] despite having lower incidence rates. However, Peru is often excluded from the few reports in Latin

¹Scientific University of the South, Lima, Peru. ²Latin American Network for Cancer Research (LAN-CANCER), Lima, Peru. ³Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA. ⁴San Luis Gonzaga National University of Ica, Ica, Peru. ⁵Department of Internal Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA. ⁶Cancer Center, Medical Center American British Cowdray, Mexico City, Mexico. ⁷Technological University of Peru, Lima, Peru. ⁸Epidemiology Unit, San José de Chíncha Hospital, Chíncha, Peru. ⁹Faculty of Health Sciences, Universidad de Huánuco, Huánuco 10001, Peru. *For Correspondence: jstorresroman@gmail.com

America, limiting our understanding of how the mortality rates in Peru has changed in recent years.

Peru is estimated to have the fourth highest liver cancer mortality rate in South America [1]. Data available from the Population-Based Cancer Registry of Metropolitan Lima [18-20] reported increases in the liver cancer mortality in Lima, the capital of Peru. Between 2004-2005 to 2013-2015, the mortality rate increased from 3.7 to 4.8 per 100,000 in men; and from 3.0 to 3.7 per 100,000 in women [21, 22, 20]. Liver cancer mortality in other regions of Peru has not been extensively explored. Therefore, the purpose of this study was to determine the trends in liver cancer mortality in Peru between 2003-2017, according to geographical area and sex.

Materials and Methods

Source of information

We conducted a descriptive epidemiology study, based on secondary data analysis using the mortality database of the Peruvian Ministry of Health. The Ministry of Health collects mortality data from all health establishments from the National Registry of Identification and Civil Status and the Public Ministry records. Liver cancer deaths were identified using the code C22 as per the International Classification of Diseases (ICD) 10th revision [23]. The information included in the registries is based on reports from health facilities located in the 25 provinces of Peru. The information is available through its online platform: <https://www.minsa.gob.pe/portada/transparencia/solicitud/>. This database has information on the number of deaths from liver cancer in Peru between 2003 and 2017. The deaths from liver cancer were classified into 5 age groups for all 25 provinces, according to the decedent's place of residence. We corrected for the underreporting rate for each province as previously described [24].

Total population per year was obtained from census data gathered by the National Institute of Statistics and Informatics [25], which is the central governing body of the National Statistical System, responsible for regulating, planning, directing, coordinating and supervising the country's official statistics [25].

Setting

Peru is divided into 25 provinces that are in one of the 3 geographical regions: coast, highlands, and the rainforest. It has a population of 31 million persons who are unevenly distributed among these regions. Although the coast only covers 12% of the territory, it is the most densely populated region with approximately 56% of the total population. The highlands represents approximately 28% of the territory, and is home to 30% of the population; while the rainforest is the largest region of the country, accounting for 60% of the territory but home to only 14% of the population [26].

Statistical analysis

We calculated age-standardized mortality rates (ASMR) per 100,000 person-years using the SEGI world standard population [27]. The Joinpoint Regression

Program Version 4.7.0 was used to calculate the estimated annual percent change, the average annual percent change, and their 95 % confidence intervals (95% CI) [28]. We identified statistically significant trend change points (joinpoints) and the rate of change in each trend segment using a Monte Carlo permutation method. A maximum number of three joinpoints was allowed. A segment was considered significant if the slope of the regression line was statistically different from zero ($p < 0.05$). The GeoDA software package was used for spatial distribution analysis [29].

Results

A total of 31,343 liver cancer deaths (14,598 in men and 16,745 in women) were reported between 2003 to 2017. Figure 1 and Table 1 shows the age standardized liver cancer mortality rates (ASMRs) per 100,000 during the entire period (2003-2017). The highest ASMRs were in Apurimac (14.0), Huanuco (13.4), and Ayacucho (13.0) for men, and Tacna (16.5), Apurimac (14.0), and Puno (13.3) for women. The lowest ASMRs (< 10.0) were observed in the rainforest provinces.

Table 2 shows the number of deaths and age-standardized mortality rates per 100,000 person-years in Peru and its regions. For Peruvian men, the ASMR decreased from 7.21 in 2003 to 6.43 in 2017, whereas in

Table 1. Average Age-Standardized Liver Cancer Mortality Rates in Peru, 2003-2017.

Provinces	Men	Women
Amazonas	9.7	9.9
Ancash	6.4	7.0
Apurimac	14.6	14.0
Arequipa	6.5	8.0
Ayacucho	13	11.2
Cajamarca	9.1	9.2
Callao	6.7	5.7
Cusco	10.5	12.5
Huancavelica	10.3	12.3
Huanuco	13.4	12.2
Ica	6.7	8.3
Junin	10	9.3
La Libertad	8.1	9.8
Lambayeque	7.9	8.9
Lima	7.3	6.6
Loreto	8	9.1
Madre de Dios	5.8	9.5
Moquegua	5.7	8.7
Pasco	8.2	11.7
Piura	8.7	9.1
Puno	6.5	13.3
San Martin	10.2	11.2
Tacna	9.7	16.5
Tumbes	6.2	8.0
Ucayali	7.5	7.2

Table 2. Number of Deaths, Age-Standardized Mortality Rates Per 100,000 Person-Years from Liver Cancer in Peru and Regions.

Geographical Areas	Men				Women				M:F Ratio (2003)	M:F Ratio (2017)
	2003		2017		2003		2017			
	Deaths	ASMR	Deaths	ASMR	Deaths	ASMR	Deaths	ASMR		
Country										
Peru	751	7.21	874	6.43	781	6.95	1065	7.1	1	0.9
Regions										
Coast	436	6.53	512	5.63	472	6.36	606	5.84	1	1
Highlands	266	9.27	283	8.46	246	8.01	383	10.46	1.2	0.8
Rainforest	49	5.66	79	6.93	63	8.66	76	7.59	0.7	0.9




Figure 1. Age-Standardized Mortality Rates for Liver Cancer from Peru, 2003–2017.

Peruvian women, the ASMR increased from 6.95 in 2003 to 7.10 in 2017. Rainforest region reported an increase for men (from 5.66 in 2003 to 6.93 in 2017), whereas the highlands region reported an increase for women (from 8.01 in 2003 to 10.46 in 2017). In 2003, the male-to-female ASMR ratio was ≥ 1 in Peru, coast, and highlands, while in the rainforest it was < 1 . In 2017, the male-to-female ASMR ratio was ≥ 1 in the coast, while was < 1 in Peru, highlands and rainforest regions. Table 3 and Figure 2 shows Joinpoint analysis of liver cancer in Peru and its regions between 2003 and 2017. In men, although the ASMRs declined in both Peru and in the individual

regions, the declines were not statistically significant. In contrast, there was a significant decrease among women in Peru overall (-3.1%) and in the coastal region (-3.5%) from 2005 to 2017, and in the highlands region (-2.8%) from 2007 to 2017.

The analysis of liver cancer mortality among men by province found that Ucayali, Apurimac, and Huancavelica had the highest mortality rates in 2003, whereas Apurimac, Ayacucho, and Cusco reported the highest mortality rates in 2017. Of these, Ancash province reported a significant increase of 12.5% per year during 2003-2011, but a significant decrease of 10.5% per year between 2011-

Table 3. Joinpoint Analysis for Liver Cancer from Peru and Its Regions between 2003 and 2017.

Geographical area	Years	Men			Years	APC	Women		
		APC	AAPC	APC			APC	AAPC	
Country									
Peru	2003-2017	-1.3 (-2.8,0.2)	-1.3 (-2.8,0.2)	2003-2005	20.2 (-1.0,45.8)	2005-2017	-3.1*(-4.2,-2.0)	-0.1 (-2.6,2.5)	
Regions									
Coast	2003-2017	-0.9 (-2.4,0.7)	-0.9 (-2.4,0.7)	2003-2005	17.3 (-6.4,47.1)	2005-2017	-3.5*(-4.8,-2.2)	-0.8 (-3.8,2.2)	
Highlands	2003-2017	-1.6 (-3.3,0.1)	-1.6 (-3.3,0.1)	2003-2007	10.2 (-0.9,22.6)	2007-2017	-2.8*(-5.3,-0.2)	-0.8 (-2.4,4.0)	
Rainforest	2003-2017	-2.7 (-6.4,1.1)	-2.7 (-6.4,1.1)	2003-2017	-2.0 (-5.4,1.5)			-2.0 (-5.4,1.5)	

* p value: < 0.05




Figure 2. Joinpoint of Liver Cancer Mortality Rates in Peru and Its Regions, 2003-2017.

2017; whereas the provinces such as Cajamarca (-3.0%), Junin (-3.0%), and Ucayali (-12.2%) reported significant decreases between 2003 and 2017 (Supplementary 1 and Supplementary 2). Among women, the provinces of Tacna, Moquegua, and Cusco reported the highest mortality rates in 2003, whereas Madre de Dios, Huanuco, and Tacna reported the highest mortality rates in 2017. The mortality rates declined significantly between 2003 and 2017 in the provinces of Arequipa (-3.8%), Cusco (-3.5%), La Libertad (-2.1%), Lima (-2.5%), and Moquegua (-6.0%), whereas in Junin province, there was an increase of 6% between 2003 and 2012, followed by, a 15.4% afterward. These changes, however, were not statistically significant (Supplementary 1 and Supplementary 2).

Discussion

This is the first study in Peru to examine liver cancer mortality patterns by region and sex from 2003 to 2017. Mortality rates ranged from 6 to 7 deaths per 100,000. Among women there was a decrease in liver cancer mortality rates, whereas among men, there were stable mortality trends. Unlike the typical male-to-female (M:F) ratio in liver cancer, the M:F ratio in Peru was at or below one between 2003 and 2017.

The liver cancer mortality rates in Peru are comparable

to those in Brazil and Chile, but are notably higher than the rates across other Latin American nations [1, 30]. Within the South American context, the primary risk factors for hepatocellular carcinoma (HCC), the most prevalent form of liver cancer, are HCV infection followed by alcoholic cirrhosis [31]. Meanwhile, some Latin American groups have witnessed a rise in HCC cases attributed to MASLD [32]. Remarkably, Peru's mortality rates in this regard rank among the highest in Latin America and the Caribbean. In Peru and among individuals aged 50 years or younger across the South American population, HBV infection is the primary cause of HCC [33, 34]. In contrast to global trends, cohort studies conducted in Peru reveal distinctive clinical profiles of HCC. The condition can notably affect persons aged less than 45 years, particularly those in the Andean population, who exhibit a normal and healthy liver. This phenomenon is paralleled by a bimodal age distribution of HCC patients in Peru, leading to two distinct subpopulations characterized by varying clinical attributes [35]. The subgroup consisting of younger ages (≤ 44 years, with a mean of 25.5 years) tends to present with a higher occurrence of poorly differentiated or undifferentiated high-grade tumors, along with distant metastases, and an elevated prevalence of HBV infection. Conversely, the HCC subgroup aged 44 years (mean of 65.5 years) displays a greater frequency of multinodular

HCC and an increased rate of HCV infection.[35] This unique clinical spectrum is further compounded by the substantial prevalence of HBV and HCV viruses within the rainforest region, particularly among the indigenous population [36].

Another contributing factor to the elevated liver cancer mortality rates in Peru could be AFB1, a widely recognized hepatocarcinogen [37]. An investigation into food items sold in Lima's markets recently revealed a notable prevalence of AFB1 contamination..An assessment of 80 liver cancer cases, however, identified the AFB1 signature mutation in codon 249 of the TP53 gene in only one case [31, 38]. However, it's worth noting that the codon 249 mutation is observed in a specific subset of individuals with liver cancer in regions of high AFB1 exposure. Therefore, the possibility of AFB1 acting as a risk factor cannot be dismissed, even in the absence of the TP53 codon 249 mutation [39].

Although Peru reported the highest mortality rates in Latin America, significant declines in rates among women occurred while rates among men remained stable.. Other studies s have reported an increase in mortality rates for Brazilian men, and a decrease for Colombian men. Meanwhile, Colombia and Ecuador have reported decreasing mortality rates for women [17]. Similarly, despite declines of 1.2 between 2018 and 2020, the most recent GLOBOCAN statistics listed Peru as having one of the highest mortality rates in Latin America and the Caribbean [30, 1]. Overall, this study found a liver cancer mortality rate of less than 10 per 100,000 persons, . Nonetheless, Peru's rates are lower than those of countries such as Guatemala and Nicaragua, where the mortality rate is above 10 per 100,000 people. These high rates are likely the result of unhealthy lifestyle factors including drinking, smoking, and unhealthy diets . The prevalence of diabetes and obesity has increased because of these factors, with obesity affecting 62.7% of persons 15 years and older, with women having the highest incidence. Obesity alone has been associated with a 4-fold increase in liver cancer deaths [40].

In Peru, we have observed irregular mortality patterns, characterized by a decline in mortality rates among women residing on the coast and in the highlands, while trends have remained relatively stable in the rainforest region. Notably, despite the rainforest's high endemicity for HBV, a prominent risk factor for liver cancer, there hasn't been a corresponding increase in this region's liver cancer mortality rates. This phenomenon is likely attributed to recent advancements in HBV control efforts [41]. The observed variations in mortality might stem from clinical and biological disparities among hepatocellular carcinoma patients born in the central-southern region. This group tends to be younger, more frequently carriers of HBV, and have lower tumor grades compared to those born in the south-central coastal regions [42]. Interestingly, the reduction in liver cancer mortality may be attributable to the successful implementation of cancer prevention initiatives, such as the Plan Esperanza program and awareness campaigns addressing HBV. . Despite these positive steps, the diversification of responsibilities within the Peruvian National Institutes of Neoplastic

Diseases, responsible for safeguarding, promoting, offering comprehensive care, and preventing neoplastic diseases, continues to pose challenges within the broader Peruvian healthcare system.

Limitation of the the current study include the usual caveats of a cancer registry analysis, such as possibility of missing data, lack of specific information on tumor characteristics, limited individual-level information, and variation in death registration completeness and quality. There is always the possibility of underreporting of deaths and the potential for some liver cancer deaths to be misclassified as other causes of death. In addition, the study lacked clinical data on underlying medical conditions and had little information on the prevalence of risk factors.

In conclusion, while mortality rates for women decreased between 2003 and 2017, rates among men were stable. Between 2003 and 2017, the traditional ratio M:F in liver cancer in Peru was equal to or less than one. Effective interventions like expanding access to healthcare and controlling the various risk factors for liver cancer are the main challenges to be overcome in our country.

Author Contribution Statement

Conceived and designed the idea: JSTR. Had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis: JSRT, GDK. Contributed to the writing of the manuscript: All authors. Contributed to the statistical analysis: JSRT, GDK. Critical revision of the manuscript: CSA, KAM. Approval of the submitted and final version: All authors.

Acknowledgements

We are grateful to the Scientific University of the South for proofreading our manuscript (PI-15-2024-0189).

Ethics approval and consent to participate

Ethical approval and consent of the participants were not necessary since this study involved the use of a previously published secondary database.

Availability of data and materials

The datasets used and/or analysed during the current study are available in the following link: <https://www.minsa.gob.pe/portada/transparencia/solicitud/>

Availability of data

This database can be requested via the website: <https://www.minsa.gob.pe/portada/transparencia/solicitud/>

Any conflict of interest

The authors declare that they have no competing interests.

References

1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global cancer observatory: Cancer today. Lyon, france:

- International agency for research on cancer. 2022. [cited 11 march, 2023]. Available from: <https://gco.iarc.fr/today>.
2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis b virus and hepatitis c virus infections to cirrhosis and primary liver cancer worldwide. *J Hepatol.* 2006;45(4):529-38. <https://doi.org/10.1016/j.jhep.2006.05.013>.
 3. Maucort-Boulch D, de Martel C, Franceschi S, Plummer M. Fraction and incidence of liver cancer attributable to hepatitis b and c viruses worldwide. *Int J Cancer.* 2018;142(12):2471-7. <https://doi.org/10.1002/ijc.31280>.
 4. Powell EE, Wong VW-S, Rinella M. Non-alcoholic fatty liver disease. *Lancet.* 2021;397(10290):2212-24. [https://doi.org/10.1016/S0140-6736\(20\)32511-3](https://doi.org/10.1016/S0140-6736(20)32511-3).
 5. Wongjarupong N, Assavapongpaiboon B, Susantitaphong P, Cheungpasitporn W, Treeprasertsuk S, Rerknimitr R, et al. Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: A systematic review and meta-analysis. *BMC Gastroenterol.* 2017;17(1):1-8. <https://doi.org/10.1186/s12876-017-0696-4>
 6. Tan DJH, Ng CH, Lin SY, Pan XH, Tay P, Lim WH, et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis. *Lancet Oncol.* 2022;23(4):521-30. [https://doi.org/10.1016/S1470-2045\(22\)00078-X](https://doi.org/10.1016/S1470-2045(22)00078-X).
 7. Rui R, Lou J, Zou L, Zhong R, Wang J, Xia D, et al. Excess body mass index and risk of liver cancer: A nonlinear dose-response meta-analysis of prospective studies. *PLoS ONE.* 2012;7(9):e44522. <https://doi.org/10.1371/journal.pone.0044522>.
 8. Chen Y, Wang X, Wang J, Yan Z, Luo J. Excess body weight and the risk of primary liver cancer: An updated meta-analysis of prospective studies. *Eur J Cancer.* 2012;48(14):2137-45. <https://doi.org/10.1016/j.ejca.2012.02.063>.
 9. Ling S, Brown K, Miksza JK, Howells L, Morrison A, Issa E, et al. Association of type 2 diabetes with cancer: A meta-analysis with bias analysis for unmeasured confounding in 151 cohorts comprising 32 million people. *Diabetes Care.* 2020;43(9):2313-22. <https://doi.org/10.2337/dc20-0204>.
 10. Bagnardi V, Blangiardo M, La Vecchia C, Corrao G. A meta-analysis of alcohol drinking and cancer risk. *Br J Cancer.* 2001;85(11):1700-5. <https://doi.org/10.1054/bjoc.2001.2140>.
 11. Turati F, Galeone C, Rota M, Pelucchi C, Negri E, Bagnardi V, et al. Alcohol and liver cancer: A systematic review and meta-analysis of prospective studies. *Ann Oncol.* 2014;25(8):1526-35. <https://doi.org/10.1093/annonc/mdl020>.
 12. Pang Q, Qu K, Zhang J, Xu X, Liu S, Song S, et al. Cigarette smoking increases the risk of mortality from liver cancer: a clinical-based cohort and meta-analysis. *J Gastroenterol Hepatol.* 2015;30(10):1450-60.
 13. Groopman JD, Smith JW, Rivera-Andrade A, Alvarez CS, Kroker-Lobos MF, Egner PA, et al. Aflatoxin and the aetiology of liver cancer and its implications for Guatemala. *World Mycotoxin J.* 2021;14(3):305-17. <https://doi.org/10.3920/wmj2020.2641>
 14. Wogan GN. Aflatoxins as risk factors for hepatocellular carcinoma in humans. *Cancer Res.* 1992;52(7 Supplement):2114s-8s.
 15. de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis. *Lancet Global Health.* 2020;8(2):e180-e90. [https://doi.org/10.1016/S2214-109X\(19\)30488-7](https://doi.org/10.1016/S2214-109X(19)30488-7).
 16. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2021;71(3):209-49. <https://doi.org/10.3322/caac.21660>
 17. Wong M, Jiang JY, Goggins WB, Liang M, Fang Y, Fung FD, et al. International incidence and mortality trends of liver cancer: A global profile. *Sci Rep.* 2017;7(1):1-9. <https://doi.org/10.1038/srep45846>.
 18. Toft N, Schmiegelow K, Klausen TW, Birgens H. Adult acute lymphoblastic leukaemia in Denmark. A national population-based retrospective study on acute lymphoblastic leukaemia in Denmark 1998-2008. *Br J Haematol.* 2012;157(1):97-104. <https://doi.org/10.1111/j.1365-2141.2011.09020.x>.
 19. Gupta S, Pole JD, Baxter NN, Sutradhar R, Lau C, Nagamuthu C, et al. The effect of adopting pediatric protocols in adolescents and young adults with acute lymphoblastic leukemia in pediatric vs adult centers: An impact cohort study. *Cancer Med.* 2019;8(5):2095-103. <https://doi.org/10.1002/cam4.2096>.
 20. Ministry of Health. National Institute of Neoplastic Diseases. Cancer Registry of Metropolitan Lima 2013-2015. Vol. vi, 2021.
 21. Ministry of Health. National Institute of Neoplastic Diseases. Cancer Registry of Metropolitan Lima 2004-2005. Vol. iv, 2013.
 22. Ministry of Health. National Institute of Neoplastic Diseases. Cancer Registry of Metropolitan Lima 2013-2015. Vol. vi, 2021.
 23. World health organization. International classification of disease and related health problems: 10th revision. Geneva. 1992.
Available from: <https://www.who.int/standards/classifications/classification-of-diseases/list-of-official-icd-10-updates.1>.
 24. Torres-Roman JS, Martinez-Herrera JF, Carioli G, Ybaseta-Medina J, Valcarcel B, Pinto JA, et al. Breast cancer mortality trends in Peruvian women. *BMC Cancer.* 2020;20(1):1-9. <https://doi.org/10.1186/s12885-020-07671-x>.
 25. National Institute of Statistics and Informatics. Demographic Analysis Bulletin No. 37. Peru: Population estimates and projections by department, sex and five-year age groups, 1995-2025. <http://proyectos.inei.gob.pe/web/biblioineipub/bancopub/Est/Lib0846/index.htm>. Accessed 10 January 2018.
 26. Torres-Roman JS, Ruiz EF, Martinez-Herrera JF, Mendes Braga SF, Taxa L, Saldaña-Gallo J, et al. Prostate cancer mortality rates in Peru and its geographical regions. *BJU Int.* 2019;123(4):595-601. <https://doi.org/10.1111/bju.14578>.
 27. Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJ, Lozano R, Inoue M. Age standardization of rates: a new WHO standard. Geneva: World Health Organization. 2001 Jan 1;9(10):1-4.
 28. National cancer institute. Joinpoint regression program. [accessed March 1, 2024]. Available in: <https://surveillance.cancer.gov/help/joinpoint>.
 29. Anselin L, Syabri I, Kho Y. Geoda: An introduction to spatial data analysis. *Geogr Anal.* 2006;38(1):5-22. <https://doi.org/10.1111/j.0016-7363.2005.00671.x>
 30. Carrilho FJ, Paranagua-Vezozzo DC, Chagas AL, Alencar RS, da Fonseca LG. Epidemiology of liver cancer in Latin America: current and future trends. In *Seminars in Liver Disease 2020 May (Vol. 40, No. 02, pp. 101-110)*. Thieme Medical Publishers.
 31. Pineau P, Ruiz E, Deharo E, Bertani S. On hepatocellular carcinoma in South America and early-age onset of the disease. *Clin Res Hepatol Gastroenterol.* 2019;43(5):522-6. <https://doi.org/10.1016/j.clinre.2018.10.019>.
 32. Farah M, Anugwom C, Ferrer JD, Baca EL, Mattos

- AZ, Possebon JPP, et al. Changing epidemiology of hepatocellular carcinoma in south america: A report from the south american liver research network. *Ann Hepatol.* 2023;28(2):100876. <https://doi.org/10.1016/j.aohep.2022.100876>.
33. Chan AJ, Balderramo D, Kikuchi L, Ballerga EG, Prieto JE, Tapias M, et al. Early age hepatocellular carcinoma associated with hepatitis b infection in south america. *Clin Gastroenterol Hepatol.* 2017;15(10):1631-2. <https://doi.org/10.1016/j.cgh.2017.05.015>.
34. Debes JD, Chan AJ, Balderramo D, Kikuchi L, Gonzalez Ballerga E, Prieto JE, et al. Hepatocellular carcinoma in south america: Evaluation of risk factors, demographics and therapy. *Liver Int.* 2018;38(1):136-43. <https://doi.org/10.1111/liv.13502>.
35. Bertani S, Pineau P, Loli S, Moura J, Zimic M, Deharo E, et al. An atypical age-specific pattern of hepatocellular carcinoma in peru: A threat for andean populations. *PLoS One.* 2013;8(6):e67756. <https://doi.org/10.1371/journal.pone.0067756>.
36. Cabezas-Sánchez C, Trujillo-Villaruel O, Zavaleta-Cortijo C, Culqui-Lévano D, Suarez-Jara M, Cueva-Maza N, et al. Prevalence of hepatitis b infection in children under 5 years old on indigenous communities of the peruvian amazonia after immunization interventions. *Rev Peru Med Exp Salud Publica.* 2014;31(2):204-10.
37. Li FQ, Yoshizawa T, Kawamura O, Luo XY, Li YW. Aflatoxins and fumonisins in corn from the high-incidence area for human hepatocellular carcinoma in guangxi, china. *J Agric Food Chem.* 2001;49(8):4122-6. <https://doi.org/10.1021/jf010143k>.
38. Rojas Jaimes J, Chacón Cruzado M, Castañeda Peláez L, Díaz Tello A. Cuantificación de aflatoxinas carcinogénicas en alimentos no procesados y su implicación para el consumo en lima, Perú. *Nutr Hosp.* 2021;38(1):146-51.
39. Valdés-Peregrina EN, Sánchez-Hernández BE, Gamboa-Domínguez AJRdic. Metabolic syndrome instead of aflatoxin-related tp53 r249s mutation as a hepatocellular carcinoma risk factor. *Rev Invest Clin.* 2020;72(5):316-22. <https://doi.org/10.24875/RIC.20000131>
40. Mathur A, Franco ES, Leone JP, Osman-Mohamed H, Rojas H, Kemmer N, et al. Obesity portends increased morbidity and earlier recurrence following liver transplantation for hepatocellular carcinoma. *HPB.* 2013;15(7):504-10. <https://doi.org/10.1111/j.1477-2574.2012.00602.x>.
41. Ormaeche M, Whittembury A, Pun M, Suárez-Ognio L. Hepatitis b virus, syphilis, and hiv seroprevalence in pregnant women and their male partners from six indigenous populations of the peruvian amazon basin, 2007–2008. *Int J Infect Dis.* 2012;16(10):e724-e30. <https://doi.org/10.1016/j.ijid.2012.05.1032>
42. Marchio A, Cerapio JP, Ruiz E, Cano L, Casavilca S, Terris B, et al. Early-onset liver cancer in south america associates with low hepatitis b virus DNA burden. *Sci Rep.* 2018;8(1):12031. <https://doi.org/10.1038/s41598-018-30229-8>.



This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.